Antineoplastic Purity Vorinostat Powder Vorinostat

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Vorinostat
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Vorinostat
• Name: Vorinostat Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Category
• Assay: >99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Density: 1.174
• Melting Point: 161-162c
• Boiling Point: N/a
• Mf: C14h20n2o3
• MW: 264.3202
• CAS: 149647-78-9
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Vorinostat
• Origin: Xian
• Production Capacity: 1000kg/Month

Product Description

Antineoplastic Purity Vorinostat Powder Vorinostat 

Product Description

Product Details

Product Name	Vorinostat
Appearance	Vorinostat Powder
Assay	>99%
MW	264.3202
MF	C14H20N2O3
Density	1.174

Vorinostat is a group of protein deacetylase (HDAC) inhibitors. It can play a role by inducing cell differentiation, blocking the cell cycle, and inducing cell regulation. Treatment of aggravation, persistence, and recurrence or ineffective cutaneous T-cell lymphoma (CTCL, a non-Hodgkin's lymphoma) after treatment with two systemic drugs. CTCL is a type of T cell carcinoma that affects the white blood cell types of the skin.

Application&Function

Vorinostat can play a role by inducing cell differentiation, blocking the cell cycle, and inducing cell regulation. Treatment of aggravation, persistence, and recurrence or ineffective cutaneous T-cell lymphoma (CTCL, a non-Hodgkin's lymphoma) after treatment with two systemic drugs. CTCL is a type of T cell carcinoma that affects the white blood cell types of the skin.For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies; treatment of CTCL; treating acute myeloid leukemia.

Specification